ArticleArchives of microbiology2026
Helicobacter pylori promote M1 macrophage polarization via JAK3-mediated activation of the SOCS3/IL2RA axis to suppress host immunity.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Helicobacter pylori (H. pylori) is a major cause of chronic gastritis and gastric cancer. Macrophages are key regulators of gastric immunity, yet the mechanisms by which H. pylori reprogram macrophage activation and suppresses host immune responses remain unclear. RAW264.7 macrophages were infected with H. pylori PMSS1. Macrophage polarization, cytokine secretion, and JAK3/STAT5-SOCS3 signaling were examined by qRT-PCR, Western blotting, flow cytometry, and ELISA. Ritlecitinib was used to inhibit JAK3. Primary naive CD4⁺ T cells were treated with macrophage-conditioned medium to assess proliferation, CD25/CD69 activation, and FoxP3⁺ Treg differentiation. SOCS3 knockdown was used to evaluate rescue effects. H. pylori significantly promoted M1 macrophage polarization, with increased CD86, iNOS, MHC II, TNF-α, and IFN-γ and decreased CD163, Arg1, TGF-β, and IL-10 (p < 0.05). H. pylori also upregulated JAK3, STAT5, and SOCS3, while Ritlecitinib attenuated inflammatory gene expression (p < 0.05). Hp-CM significantly inhibited primary CD4⁺ T-cell proliferation, CD25/CD69 activation, and CD4⁺CD25⁺FoxP3⁺ Treg differentiation (p < 0.05). SOCS3 knockdown partially restored these CD4⁺ T-cell responses (p < 0.05). H. pylori promotes M1 macrophage polarization and impairs CD4⁺ T-cell immunity through JAK3/STAT5-SOCS3-mediated immune dysregulation. This mechanism contributes to chronic immune dysregulation and supports bacterial persistence, identifying JAK3/SOCS3 as potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.